Torrent Pharmaceuticals Q2 FY27 Results: Revenue Rises 51% To ₹4,979 Crore, While Net Profit Falls 10%

  • Posted: 23 Oct 2026, 7:59 PM IST
  • 1.5 Min. Read
Add Preferred News SourceAdd Preferred News Source
Torrent Pharmaceuticals Q2 FY27 Results: Revenue Rises 51% To ₹4,979 Crore, While Net Profit Falls 10%
Torrent Pharma Q2 FY27 revenue crosses ₹4,900 crore, but profit falls despite higher operating earnings.
Summary

Torrent Pharmaceuticals reported 50.8% YoY growth in consolidated revenue to ₹4,979 crore in Q2 FY27. Operating EBITDA rose 53.8% to ₹1,666 crore, but profit after tax fell 9.6% to ₹534 crore.

Torrent Pharmaceuticals reported consolidated revenue of ₹4,979 crore in Q2 FY27, an increase of 50.8% year-on-year (YoY). Operating earnings before interest, tax, depreciation and amortisation (EBITDA) before exceptional items rose 53.8% to ₹1,666 crore, while profit after tax (PAT) declined 9.6% to ₹534 crore.

The company’s base business recorded 18% revenue growth, supported by its India, Brazil and US operations. However, the integration of the JB business following the merger had a temporary impact on revenue during the quarter.

The Torrent Pharma share price closed at ₹4,524.40 on 23 October 2026 on the National Stock Exchange (NSE), down almost 2%.

Torrent Pharma Q2 Results: Other Key Highlights

Gross profit rose 50.1% to ₹3,755 crore, with gross margin at 75.4%, compared with 75.8% a year earlier. Operating EBITDA margin improved to 33.5% from 32.8%.

Research and development (R&D) expenditure increased 35% to ₹211 crore, accounting for 4.2% of revenue. For H1 FY27, revenue grew 52.8% to ₹9,900 crore, and operating EBITDA rose 57.4% to ₹3,330 crore. PAT fell 3.4% to ₹1,100 crore.

Torrent Pharma’s Regional Revenue Performance

India revenue increased 20% to ₹2,181 crore, ahead of the 12% growth reported for the Indian pharmaceutical market, according to PharmaTrac. Torrent’s generic semaglutide products held a combined 32% market share across oral and injectable formulations.

Brazil revenue rose 38% to ₹440 crore, while US revenue grew 24% to ₹417 crore, supported by new launches. Germany revenue declined 7% to ₹283 crore amid third-party supplier disruptions and the loss of certain high-volume tenders.

Torrent said integration of the India business, optimisation of its global network and alignment of manufacturing and quality systems following the merger with JB, effective 8 July 2026, temporarily affected revenue during Q2 FY27.

Also Read - Tata Motors Q2 FY27 Results: Consolidated Revenue Rises 36% To ₹25,338 Crore, Company Returns To Profit

This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer

About the Author
Vishwa Ved
Vishwa Ved

Vishwa has spent 10+ years across fintech and FMCG doing what most people miss, connecting the dots, catching trends before they trend, and finding the angle nobody else thought to ask about.

At Kotak Neo, she drives content strategy for neoshorts, Kotak News Desk, and Investing Guide, turning market noise into something worth reading.

When she's not decoding markets, she trades charts for canvases, chasing art, painting, and architecture across cities she's yet to explore.

Latest News